Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

doi:10.1200/JCO.2008.21.6796

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Dec 2009

Laurent-Puig Pierre, Cayre Anne, Manceau Gilles, Buc Emmanuel, Bachet Jean-Baptiste, Lecomte Thierry, Rougier Philippe, Lievre Astrid, Landi Bruno, Boige Valérie, Ducreux Michel, Ychou Marc, Bibeau Fréderic, Bouché Olivier, Reid Julia, Stone Steven, Penault-Llorca Frédérique

Abstract excerpt

PURPOSE: The occurrence of KRAS mutation is predictive of nonresponse and shorter survival in patients treated by anti-epidermal growth factor receptor (anti-EGFR) antibody for metastatic colorectal cancer (mCRC), leading the European Medicine Agency to limit its use to patients with wild-type KRAS tumors. However, only half of these patients will benefit from treatment, suggesting the need to identify additional...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cetuximab

Share to Disease-Free Survival

Share to France

Share to Gene Amplification

Share to Patient Selection

Share to Proportional Hazards Models

Share to PTEN Phosphohydrolase

Source

Open in PubMed

Identifiers

PMID: 19884556
DOI: 10.1200/JCO.2008.21.6796

Genes

EGFR
KRAS
BRAF
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.PMID 19884556Read ↗

EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab.Semantic proximity Read ↗

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.Semantic proximity Read ↗

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patientsSemantic proximity Read ↗

Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer.Semantic proximity Read ↗

Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.Semantic proximity Read ↗

Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS.Semantic proximity Read ↗

The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.Semantic proximity Read ↗

Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients.Semantic proximity Read ↗

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Semantic proximity Read ↗

Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: a single center study.Semantic proximity Read ↗

KRAS mutations and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal carcinoma: an open issue.Semantic proximity Read ↗

PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.